Is this your company? Get featured or correct your listing →
Investors
Latest Pulse
- Sep 22, 2026This Fall's Biotech IPOs Are Splitting Into Pops And DropsRecent biotech IPO debuts have split sharply: Parabilis Medicines popped 66.75% and BillionToOne jumped 66.67% on debut, while Electra Therapeutics closed down nearly 12% this week -- a mixed signal inside one reopened window.→
- Sep 21, 2026Electra Therapeutics Closes First Day Down 12%Electra Therapeutics priced its upsized IPO at $15 a share for roughly $350 million, then closed its first trading day on Nasdaq down nearly 12% at $13.25 -- a rockier debut than the biotech IPO market's recent run of first-day pops.→
- Aug 31, 2026Biotech Funding Held Its Ground While AI Took the OxygenGlobal biotech startup investment is tracking to its usual $36 billion to $40 billion range in 2026 despite the AI capital surge, with more than $6 billion of that going to AI-native drug discovery companies.→
- Aug 2, 2026Biotech IPOs Are Upsizing Mid-Roadmap in 2026Several of 2026's biotech IPOs have expanded their target raise between initial filing and pricing, a sign the sector's strong average return this year has pulled in enough demand that bankers are re-cutting deal size on the fly.→
- Jul 7, 2026Biotech's IPO Window Reopens With Record DebutsA run of 2026 biotech IPOs, led by Parabilis Medicines and Kailera Therapeutics, has broken records once held by Moderna, signaling the biotech public-market window has genuinely reopened after years of caution.→
Coverage Timeline
newest firstAll Coverage
IPO
This Fall's Biotech IPOs Are Splitting Into Pops And Drops
Recent biotech IPO debuts have split sharply: Parabilis Medicines popped 66.75% and BillionToOne jumped 66.67% on debut, while Electra Therapeutics closed down nearly 12% this week -- a mixed signal inside one reopened window.
BY THE NUMBERS
Biotech's IPO Window Reopens With Record Debuts
IPO$670M-$719M record biotech raises
Biotech's IPO Window Reopens With Record Debuts
A run of 2026 biotech IPOs, led by Parabilis Medicines and Kailera Therapeutics, has broken records once held by Moderna, signaling the biotech public-market window has genuinely reopened after years of caution.
Related Companies
Parabilis Medicines FAQ
Who are Parabilis Medicines's investors?
Parabilis Medicines's investors include ARCH Venture Partners, Nextech Invest, venBio Partners.